論文・技術情報追加のお知らせ

1. Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis.

抗精神病薬が肺塞栓症リスクを増加させる可能性

対象DB：FAERS

2. Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database.

薬剤による勃起不全リスクの詳細な解析結果

対象DB：FAERS

3. A real-world pharmacovigilance study of cardiac adverse events induced by sugammadex in the FDA adverse event reporting system.

スガマデックスの心臓副作用に関する大規模解析

対象DB：FAERS

4. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

ファクターVIII製品とエミシズマブの血栓性副作用比較

対象DB：FAERS

5. Are Alpha-2 Adrenergic Agonists Being Used in Infants?

ブリモニジン使用の乳児における副作用として、低緊張症や中枢神経抑制が確認

対象DB：FAERS

6. Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS).

テリパラチドの副作用分析、主要な副作用として骨折やカルシウム増加が確認

対象DB：FAERS

7. Erythema multiforme associated with the immune checkpoint inhibitors: A disproportionality analysis using the FDA Adverse Event Reporting System.

免疫チェックポイント阻害剤による紅斑多形の副作用分析

対象DB：FAERS

8. Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system.

フィネレノンの使用で新たな副作用シグナルが確認され、安全性向上が期待される

対象DB：FAERS

9. Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database.

DORA使用で「睡眠麻痺」などの副作用シグナルが検出され、安全性向上が期待される

対象DB：FAERS

10. Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer's Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System.

AD患者のSGA使用で心臓や腎臓の副作用が増加する可能性

対象DB：FAERS

11. A Real World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten.

マバカメンの副作用分析で心不全や心房細動が報告された

対象DB：FAERS

12. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.

ガルサルファーゼの副作用をFAERSで分析

対象DB：FAERS

13. What's the harm? Results of an active surveillance adverse event reporting system for chiropractors and physiotherapists.

カイロ/理学療法後の副作用の発生率と重症度を調査

対象DB：FAERS

14. Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system.

膀胱癌治療薬で新たな副作用シグナルを発見

対象DB：FAERS

15. Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system.

ボルテゾミブで新たな副作用（敗血症、結腸炎）発見

対象DB：FAERS

16. Novel insights into post-marketing AEs associated with leuprorelin: A comprehensive analysis utilizing the FAERS database.

ルプロレリンの新たな副作用を発見し、安全性向上に寄与

対象DB：FAERS

17. Characteristics of eye disorders induced by atypical antipsychotics: a real-world study from 2016 to 2022 based on Food and Drug Administration Adverse Event Reporting System.

非定型抗精神病薬による眼科的副作用に差があり、オランザピンが眼球震盪で強いシグナルを示す

対象DB：FAERS

18. Catatonia related to tacrolimus: a real world pharmacovigilance study of FDA adverse event reporting system (FAERS) database.

タクロリムスは40歳以上でカタトニアのリスクが高い

対象DB：FAERS

19. Occurrence of somnolence and respiratory depression induced by pregabalin and mirogabalin use and the influence of opioid treatment using the Japanese adverse drug event report database.

ミロガバリンはオピオイドと併用しても眠気の頻度が増加しないが、プレガバリンは増加する

対象DB：JADER

20. Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data.

COVID-19ワクチンの重篤な心臓副作用は稀で、利点がリスクを上回る

対象DB：EudraVigilance

21. Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database.

ワクチン関連リウマチ疾患は稀であるが、COVID-19 mRNAとHBVワクチンでの報告が増加

対象DB：VigiBase

22. Timing of Direct Oral Anticoagulants Resumption Following Colorectal Endoscopic Submucosal Dissection: A Nationwide Study in Japan.

大腸ESD後、DOACを翌日再開すると血栓症リスクが低下し、出血リスクは増加しない

対象DB：DPC

23. Effects of Rotavirus Vaccination Coverage among Infants on Hospital Admission for Gastroenteritis across All Age Groups, Japan, 2011-2019.

ロタウイルスワクチン接種率が高いほど、全年齢層の胃腸炎入院が減少

対象DB：DPC

24. Analysis of thromboembolism and prognosis in metastatic pancreatic cancer from the Tokushukai REAl World data project.

転移性膵癌患者の10.2%に癌関連血栓症が発生し、予後が悪化する

対象DB：DPC

25. Impact of the coronavirus disease 2019 pandemic on the number of colorectal cancer surgeries performed: analysis of a nationwide inpatient database in Japan.

COVID-19パンデミック中、進行度によって大腸癌手術数が変動

対象DB：DPC

26. Outcome research on esophagectomy analyzed using nationwide databases in Japan: evidences generated from real-world data.

日本の大規模データベースで食道癌手術の品質向上と成果分析が進行中

対象DB：DPC

27. Delayed global standardization and prefectural disparities in systematic lupus erythematosus treatment in Japan: a nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.

日本のSLE治療には標準化の遅れと都道府県間の格差が見られる

対象DB：NDB

28. Regional difference in multi-psychotropic drug prescription in Japan and its associated factors: an ecological study using national health insurance claims data.

日本の北部で多剤処方が多く、地域の教育水準や医師数が関連

対象DB：NDB

29. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.

日本ではDPP-4阻害剤が最も多く処方され、コストはビグアナイド使用で最も低い

対象DB：NDB

30. Tuberculosis risk in patients with Crohn's disease on biologics: a retrospective analysis of the Japanese Medical Claims Database.

TNFα阻害剤はクローン病患者の活動性結核リスクを高めるが、USTやVDZは影響なし

対象DB：MDV

31. Healthcare utilisation and associated costs for methadone versus buprenorphine recipients: Examination of interlinked primary and secondary care electronic health records in England.

メサドン使用者はブプレノルフィン使用者に比べ、入院率が高く、医療費もやや増加

対象DB：CPRD

32. Age and sex specific thresholds for risk stratification of cardiovascular disease and clinical decision making: prospective open cohort study.

年齢と性別に基づいたリスク閾値でスタチン治療を行うと、心血管疾患予防の効果が高まる可能性がある

対象DB：CPRD

33. Incidence, antimicrobial prescribing practice and associated healthcare costs of paediatric otorrhoea in primary care in the UK: A longitudinal population study.

小児耳漏は英国で年間4万件の診療負担があり、抗菌薬処方が多い

対象DB：CPRD

34. Respiratory Syncytial Virus Hospital Admission Rates and Patients' Characteristics Before the Age of 2 Years in England, 2015-2019.

英国ではRSVによる入院率は過小評価され、予防接種が全乳児を保護する必要がある

対象DB：CPRD

35. The incidence of lung cancer amongst primary care chest radiograph referrals; an evaluation of national and local datasets within the UK.

胸部X線検査による肺がんリスクは年齢と喫煙で予測可能

対象DB：CPRD

36. UK Electronic Healthcare Records for Research: A Scientometric Analysis of Respiratory, Cardiovascular, and COVID-19 Publications.

EHRデータを用いた呼吸器疾患の研究は増加傾向にあるが、心血管疾患の方が多い

対象DB：CPRD,GPRD,THIN

37. Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users.

ジクロキサシリンはDOACの吸収を減少させるが臨床的影響はなし

対象DB：CPRD

38. Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021.

2000-2021年の英国における乳がんの性別別動向を調査

対象DB：CPRD